Fattouma Bourguiba Hospital, Monastir Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04597775
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

emergency department of Fattouma Bourguiba Monastir | Fattouma Bourguiba, Tunisia

Active Ingredients

Drugs in Phase 3 Trials (1)

hydroxychloroquine (plaquenil) (1 trial)

Drugs in Other Trials (1)

zinc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2